Michal Svoboda
Michal Svoboda has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Kristian Brat
Department of Respiratory Diseases, University Hospital Brno
5 shared publications - Ivan Cundrle
Department of Anesthesiology and Intensive Care, St. Anne’s University Hospital Brno
4 shared publications Lyle J. Olson
Department of Sports Medicine and Rehabilitation, St. Anne's University Hospital, Brno
3 shared publicationsPavel Homolka
Faculty of Medicine, Masaryk University, Brno, Czech Republic
3 shared publications- Ales Linhart
2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital , Prague
2 shared publications - Jiri Litzman
Department of Clinical Immunology and Allergology St. Anne'´s University Hospital in Brno Brno Czech Republic
2 shared publications
Latest Publications
- Open Access
- 7 June 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (8) , 986-988
Registry‐Based Analysis of Treatment and Retreatment Attacks of Hereditary Angioedema
Summary: Retreatment occurs in approximately 15% of treated hereditary angioedema attacks in real‐world practice. Abdominal attacks, multisite involvement and treatment choice are associated with retreatment occurrence.
- 7 June 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (8) , 986-988
Open AccessRegistry‐Based Analysis of Treatment and Retreatment Attacks of Hereditary Angioedema
Summary: Retreatment occurs in approximately 15% of treated hereditary angioedema attacks in real‐world practice. Abdominal attacks, multisite involvement and treatment choice are associated with retreatment occurrence.
- Open Access
- 6 May 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-15
Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study
Introduction: Studies indicate that chronic treatment with mucoactive drugs may reduce COPD exacerbation rates. This real-world, multicenter, prospective, observational study aimed to determine the effect of long-term mucoactive treatment on exacerbations in patients with COPD in the Czech Republic. Methods: 452 adult patients on the Czech Multicenter Research Database of COPD with post-bronchodilator FEV 1 ≤ 60% of predicted value received standard of care and were followed up for 5 years. For the first 24 months, 81 patients received regular thiol-based mucoactive drugs (77 erdosteine, 4 N-acetylcysteine) at the discretion of the treating physician and 371 patients had no mucoactive treatment (control group). Erdosteine was fully reimbursed, and NAC was partially reimbursed for COPD patients. The annual number/rate of COPD exacerbations over 5 years was monitored. Results: Patients receiving mucoactive treatment for 24 months had a significantly larger reduction from baseline in all exacerbations compared to the control group (− 0.61 vs − 0.18, p = 0.026; − 0.54 vs − 0.09, p = 0.007; − 0.55 vs 0.04, p = 0.005; − 0.67 vs 0.13, p = 0.002; − 0.53 vs 0.10, p = 0.019 in the first to fifth year, respectively). The reduction in moderate exacerbations was also significantly larger in those receiving mucoactive treatment versus no mucoactive treatment. The exacerbation rate was reduced to a greater extent in the subgroups with cough or with stage 3‒4 COPD who received mucoactive treatment but was independent of the use of inhaled corticosteroids (ICS). Conclusion: Mucoactive treatment for two years reduced the number of COPD exacerbations (all, moderate) over five years of follow-up. The reduction in exacerbations was more pronounced in patients with cough or with stage 3‒4 COPD but was independent of the use of ICS.
- 6 May 2025
- Published by Springer Nature in Lung
- Vol. 203 (1) , 1-15
Open AccessEffect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study
Introduction: Studies indicate that chronic treatment with mucoactive drugs may reduce COPD exacerbation rates. This real-world, multicenter, prospective, observational study aimed to determine the effect of long-term mucoactive treatment on exacerbations in patients with COPD in the Czech Republic. Methods: 452 adult patients on the Czech Multicenter Research Database of COPD with post-bronchodilator FEV 1 ≤ 60% of predicted value received standard of care and were followed up for 5 years. For the first 24 months, 81 patients received regular thiol-based mucoactive drugs (77 erdosteine, 4 N-acetylcysteine) at the discretion of the treating physician and 371 patients had no mucoactive treatment (control group). Erdosteine was fully reimbursed, and NAC was partially reimbursed for COPD patients. The annual number/rate of COPD exacerbations over 5 years was monitored. Results: Patients receiving mucoactive treatment for 24 months had a significantly larger reduction from baseline in all exacerbations compared to the control group (− 0.61 vs − 0.18, p = 0.026; − 0.54 vs − 0.09, p = 0.007; − 0.55 vs 0.04, p = 0.005; − 0.67 vs 0.13, p = 0.002; − 0.53 vs 0.10, p = 0.019 in the first to fifth year, respectively). The reduction in moderate exacerbations was also significantly larger in those receiving mucoactive treatment versus no mucoactive treatment. The exacerbation rate was reduced to a greater extent in the subgroups with cough or with stage 3‒4 COPD who received mucoactive treatment but was independent of the use of inhaled corticosteroids (ICS). Conclusion: Mucoactive treatment for two years reduced the number of COPD exacerbations (all, moderate) over five years of follow-up. The reduction in exacerbations was more pronounced in patients with cough or with stage 3‒4 COPD but was independent of the use of ICS.
- Open Access
- 7 November 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (2)
Causes of ventilatory inefficiency in lung resection candidates
Introduction: Ventilatory efficiency (V′E/V′CO2) has been shown to predict postoperative pulmonary complications (PPCs) in lung resection candidates.V′E/V′CO2is determined by arterial partial pressure of carbon dioxide (PaCO2) and by dead space to tidal volume ratio (VD/VT). We hypothesisedPaCO2andVD/VTcontribute equally to the increase inV′E/V′CO2in lung resection patients.Methods: Consecutive lung resection candidates from two prior prospective studies were included in thispost hocanalysis. All subjects underwent preoperative spirometry, cardiopulmonary exercise testing and arterial blood gas analysis at rest and peak exercise. PPCs were prospectively assessed during the first 30 postoperative days, or hospital stay. A t-test, Mann–Whitney U-test and two-tailed Fisher's exact test were used to compare patients with and without PPCs. p-values V′E/V′CO2ratio both at rest and peak exercise. Both ratios were independently associated with PPCs. At rest, the contribution ofPaCO2andVD/VTto the increase inV′E/V′CO2ratio in patients with PPCs was 45% and 55%, respectively. At peak exercise, the contribution ofPaCO2andVD/VTto the increase inV′E/V′CO2ratio was 16% and 84%, respectively.Conclusions: VD/VT(V′/Q′ mismatch and/or rapid shallow breathing pattern) is the dominant contributor to the increase inV′E/V′CO2in lung resection candidates who develop PPCs.
- 7 November 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (2)
Open AccessCauses of ventilatory inefficiency in lung resection candidates
Introduction: Ventilatory efficiency (V′E/V′CO2) has been shown to predict postoperative pulmonary complications (PPCs) in lung resection candidates.V′E/V′CO2is determined by arterial partial pressure of carbon dioxide (PaCO2) and by dead space to tidal volume ratio (VD/VT). We hypothesisedPaCO2andVD/VTcontribute equally to the increase inV′E/V′CO2in lung resection patients.Methods: Consecutive lung resection candidates from two prior prospective studies were included in thispost hocanalysis. All subjects underwent preoperative spirometry, cardiopulmonary exercise testing and arterial blood gas analysis at rest and peak exercise. PPCs were prospectively assessed during the first 30 postoperative days, or hospital stay. A t-test, Mann–Whitney U-test and two-tailed Fisher's exact test were used to compare patients with and without PPCs. p-values V′E/V′CO2ratio both at rest and peak exercise. Both ratios were independently associated with PPCs. At rest, the contribution ofPaCO2andVD/VTto the increase inV′E/V′CO2ratio in patients with PPCs was 45% and 55%, respectively. At peak exercise, the contribution ofPaCO2andVD/VTto the increase inV′E/V′CO2ratio was 16% and 84%, respectively.Conclusions: VD/VT(V′/Q′ mismatch and/or rapid shallow breathing pattern) is the dominant contributor to the increase inV′E/V′CO2in lung resection candidates who develop PPCs.
- Open Access
- 16 May 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (4)
New models for prediction of postoperative pulmonary complications in lung resection candidates
Introduction: In recent years, ventilatory efficiency (minute ventilation (V′E)/carbon dioxide production (V′CO2) slope) and partial pressure of end-tidal carbon dioxide (PETCO2) have emerged as independent predictors of postoperative pulmonary complications (PPC). Single parameters may give only partial information regarding periprocedural hazards. Accordingly, our aim was to create prediction models with improved ability to stratify PPC risk in patients scheduled for elective lung resection surgery.Methods: Thispost hocanalysis was comprised of consecutive lung resection candidates from two prior prospective trials. All individuals completed pulmonary function tests and cardiopulmonary exercise testing (CPET). Logistic regression analyses were used for identification of risk factors for PPC that were entered into the final risk prediction models. Two risk models were developed; the first used restPETCO2(for patients with no available CPET data), the second usedV′E/V′CO2slope (for patients with available CPET data). Receiver operating characteristic analysis with the De-Long test and area under the curve (AUC) were used for comparison of models.Results: The dataset from 423 patients was randomly split into the derivation (n=310) and validation (n=113) cohorts. Two final models were developed, both including sex, thoracotomy, “atypical” resection and forced expiratory volume in 1 s/forced vital capacity ratio as risk factors. In addition, the first model also included restPETCO2, while the second model usedV′E/V′CO2slope from CPET. AUCs of risk scores were 0.795 (95% CI: 0.739–0.851) and 0.793 (95% CI: 0.737–0.849); both p<0.001. No differences in AUCs were found between the derivation and validation cohorts.Conclusions: We created two multicomponental models for PPC risk prediction, both having excellent predictive properties.
- 16 May 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (4)
Open AccessNew models for prediction of postoperative pulmonary complications in lung resection candidates
Introduction: In recent years, ventilatory efficiency (minute ventilation (V′E)/carbon dioxide production (V′CO2) slope) and partial pressure of end-tidal carbon dioxide (PETCO2) have emerged as independent predictors of postoperative pulmonary complications (PPC). Single parameters may give only partial information regarding periprocedural hazards. Accordingly, our aim was to create prediction models with improved ability to stratify PPC risk in patients scheduled for elective lung resection surgery.Methods: Thispost hocanalysis was comprised of consecutive lung resection candidates from two prior prospective trials. All individuals completed pulmonary function tests and cardiopulmonary exercise testing (CPET). Logistic regression analyses were used for identification of risk factors for PPC that were entered into the final risk prediction models. Two risk models were developed; the first used restPETCO2(for patients with no available CPET data), the second usedV′E/V′CO2slope (for patients with available CPET data). Receiver operating characteristic analysis with the De-Long test and area under the curve (AUC) were used for comparison of models.Results: The dataset from 423 patients was randomly split into the derivation (n=310) and validation (n=113) cohorts. Two final models were developed, both including sex, thoracotomy, “atypical” resection and forced expiratory volume in 1 s/forced vital capacity ratio as risk factors. In addition, the first model also included restPETCO2, while the second model usedV′E/V′CO2slope from CPET. AUCs of risk scores were 0.795 (95% CI: 0.739–0.851) and 0.793 (95% CI: 0.737–0.849); both p<0.001. No differences in AUCs were found between the derivation and validation cohorts.Conclusions: We created two multicomponental models for PPC risk prediction, both having excellent predictive properties.
- Open Access
- 16 January 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (3) , 177-188
Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial
BACKGROUND: Physical activity is pivotal in managing heart failure with reduced ejection fraction, and walking integrated into daily life is an especially suitable form of physical activity. This study aimed to determine whether a 6-month lifestyle walking intervention combining self-monitoring and regular telephone counseling improves functional capacity assessed by the 6-minute walk test (6MWT) in patients with stable heart failure with reduced ejection fraction compared with usual care. METHODS: The WATCHFUL trial (Pedometer-Based Walking Intervention in Patients With Chronic Heart Failure With Reduced Ejection Fraction) was a 6-month multicenter, parallel-group randomized controlled trial recruiting patients with heart failure with reduced ejection fraction from 6 cardiovascular centers in the Czech Republic. Eligible participants were ≥18 years of age, had left ventricular ejection fraction P =0.345, n=186). The intervention group increased their average daily step count by 1420 (95% CI, 749 to 2091) and daily minutes of moderate to vigorous physical activity by 8.2 (95% CI, 3.0 to 13.3) over the control group. No between-group differences were detected for any other secondary outcomes. CONCLUSIONS: Whereas the lifestyle intervention in patients with heart failure with reduced ejection fraction improved daily steps by about 25%, it failed to demonstrate a corresponding improvement in functional capacity. Further research is needed to understand the lack of association between increased physical activity and functional outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03041610.
- 16 January 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (3) , 177-188
Open AccessLifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial
BACKGROUND: Physical activity is pivotal in managing heart failure with reduced ejection fraction, and walking integrated into daily life is an especially suitable form of physical activity. This study aimed to determine whether a 6-month lifestyle walking intervention combining self-monitoring and regular telephone counseling improves functional capacity assessed by the 6-minute walk test (6MWT) in patients with stable heart failure with reduced ejection fraction compared with usual care. METHODS: The WATCHFUL trial (Pedometer-Based Walking Intervention in Patients With Chronic Heart Failure With Reduced Ejection Fraction) was a 6-month multicenter, parallel-group randomized controlled trial recruiting patients with heart failure with reduced ejection fraction from 6 cardiovascular centers in the Czech Republic. Eligible participants were ≥18 years of age, had left ventricular ejection fraction P =0.345, n=186). The intervention group increased their average daily step count by 1420 (95% CI, 749 to 2091) and daily minutes of moderate to vigorous physical activity by 8.2 (95% CI, 3.0 to 13.3) over the control group. No between-group differences were detected for any other secondary outcomes. CONCLUSIONS: Whereas the lifestyle intervention in patients with heart failure with reduced ejection fraction improved daily steps by about 25%, it failed to demonstrate a corresponding improvement in functional capacity. Further research is needed to understand the lack of association between increased physical activity and functional outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03041610.
- Open Access
- 6 July 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (4)
Endobronchial cryobiopsy may shorten the time to cancer diagnosis: a retrospective study
Introduction Endobronchial cryobiopsy (ECB) from visualized intraluminal tumor lesions is superior to forceps biopsy (FB) in terms of diagnostic yield, with acceptable safety profile. However, it is not clear, if ECB also shortens the time to morphological diagnosis. Our aim was to assess the diagnostic yield, safety, rate of diagnostic failure, and time to diagnosis of ECB, compared to FB. Methods A retrospective single-center study. All patients with visualized endobronchial tumor lesions that underwent diagnostic bronchoscopy between January 1st, 2018 and December 31st, 2020 at the Department of Respiratory Diseases, University Hospital Brno, were included. The Shapiro-Wilk test was used to evaluate normality; Mann-Whitney U test and two-tailed Fisher exact test for group comparisons; p values versus 3; pversus 8 days; pversus 2%; p<0.01). Repeated biopsy was more frequent in the forceps group (9% vs 2%; p<0.01). Post-procedural bleeding was more frequent in the cryobiopsy group; severe bleeding was absent in both groups. Conclusions We concluded that ECB from visualized intraluminal tumor lesions may shorten the time to morphological diagnosis, has an excellent diagnostic yield and safety profile.
- 6 July 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (4)
Open AccessEndobronchial cryobiopsy may shorten the time to cancer diagnosis: a retrospective study
Introduction Endobronchial cryobiopsy (ECB) from visualized intraluminal tumor lesions is superior to forceps biopsy (FB) in terms of diagnostic yield, with acceptable safety profile. However, it is not clear, if ECB also shortens the time to morphological diagnosis. Our aim was to assess the diagnostic yield, safety, rate of diagnostic failure, and time to diagnosis of ECB, compared to FB. Methods A retrospective single-center study. All patients with visualized endobronchial tumor lesions that underwent diagnostic bronchoscopy between January 1st, 2018 and December 31st, 2020 at the Department of Respiratory Diseases, University Hospital Brno, were included. The Shapiro-Wilk test was used to evaluate normality; Mann-Whitney U test and two-tailed Fisher exact test for group comparisons; p values versus 3; pversus 8 days; pversus 2%; p<0.01). Repeated biopsy was more frequent in the forceps group (9% vs 2%; p<0.01). Post-procedural bleeding was more frequent in the cryobiopsy group; severe bleeding was absent in both groups. Conclusions We concluded that ECB from visualized intraluminal tumor lesions may shorten the time to morphological diagnosis, has an excellent diagnostic yield and safety profile.
- Open Access
- 24 November 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (2)
The risk of post-operative pulmonary complications in lung resection candidates with normal forced expiratory volume in 1 s and diffusing capacity of the lung for carbon monoxide: a prospective multicentre study
Introduction: According to the guidelines for preoperative assessment of lung resection candidates, patients with normal forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) are at low risk for post-operative pulmonary complications (PPC). However, PPC affect hospital length of stay and related healthcare costs. We aimed to assess risk of PPC for lung resection candidates with normal FEV1andDLCO(>80% predicted) and identify factors associated with PPC.Methods: 398 patients were prospectively studied at two centres between 2017 and 2021. PPC were recorded from the first 30 post-operative days. Subgroups of patients with and without PPC were compared and factors with significant difference were analysed by uni- and multivariate logistic regression.Results: 188 subjects had normal FEV1andDLCO. Of these, 17 patients (9%) developed PPC. Patients with PPC had significantly lower pressure of end-tidal carbon dioxide (PETCO2) at rest (27.7versus29.9; p=0.033) and higher ventilatory efficiency (V′E/V′CO2) slope (31.1versus28; p=0.016) compared to those without PPC. Multivariate models showed association between restingPETCO2(OR 0.872; p=0.035) andV′E/V′CO2slope (OR 1.116; p=0.03) and PPC. In both models, thoracotomy was strongly associated with PPC (OR 6.419; p=0.005 and OR 5.884; p=0.007, respectively). Peak oxygen consumption failed to predict PPC (p=0.917).Conclusions: RestingPETCO2adds incremental information for risk prediction of PPC in patients with normal FEV1andDLCO. We propose restingPETCO2be an additional parameter to FEV1andDLCOfor preoperative risk stratification.
- 24 November 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (2)
Open AccessThe risk of post-operative pulmonary complications in lung resection candidates with normal forced expiratory volume in 1 s and diffusing capacity of the lung for carbon monoxide: a prospective multicentre study
Introduction: According to the guidelines for preoperative assessment of lung resection candidates, patients with normal forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) are at low risk for post-operative pulmonary complications (PPC). However, PPC affect hospital length of stay and related healthcare costs. We aimed to assess risk of PPC for lung resection candidates with normal FEV1andDLCO(>80% predicted) and identify factors associated with PPC.Methods: 398 patients were prospectively studied at two centres between 2017 and 2021. PPC were recorded from the first 30 post-operative days. Subgroups of patients with and without PPC were compared and factors with significant difference were analysed by uni- and multivariate logistic regression.Results: 188 subjects had normal FEV1andDLCO. Of these, 17 patients (9%) developed PPC. Patients with PPC had significantly lower pressure of end-tidal carbon dioxide (PETCO2) at rest (27.7versus29.9; p=0.033) and higher ventilatory efficiency (V′E/V′CO2) slope (31.1versus28; p=0.016) compared to those without PPC. Multivariate models showed association between restingPETCO2(OR 0.872; p=0.035) andV′E/V′CO2slope (OR 1.116; p=0.03) and PPC. In both models, thoracotomy was strongly associated with PPC (OR 6.419; p=0.005 and OR 5.884; p=0.007, respectively). Peak oxygen consumption failed to predict PPC (p=0.917).Conclusions: RestingPETCO2adds incremental information for risk prediction of PPC in patients with normal FEV1andDLCO. We propose restingPETCO2be an additional parameter to FEV1andDLCOfor preoperative risk stratification.
- 13 June 2022
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (8) , 994-997
Registry‐based analysis of Icatibant and C1‐inhibitor use in treatment of laryngeal attacks of hereditary angioedema
- 13 June 2022
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (8) , 994-997
Registry‐based analysis of Icatibant and C1‐inhibitor use in treatment of laryngeal attacks of hereditary angioedema
- 2 October 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (6) , 2295-2306
Time in remission as an alternative outcome measure for rheumatoid arthritis: a 10-year prospective study of 2618 new users of anti-TNF
Objective: Achieving targeted disease activity (DA) is the primary therapeutic strategy in RA. Point measurements of DA are done at out-patient visits, however true DA between visits remains unobserved. This study sought to describe and validate a new outcome measure, i.e. time in remission (TIR). Methods: Patients were enrolled in the Czech ATTRA-RA registry. TIR was calculated using linear interpolation of the DAS28-ESR determined at outpatient visits. Correlation coefficients were computed between TIR and DAS28-CRP, HAQ, Simple Disease Activity Index (SDAI), patient global assessment (PGA) and physician global assessment (PhGA). Using logistic regression, TIR was used as a predictor of remission (SDAI ≤3.3) and non-disability (HAQ <0.5). The predictive value of TIR was compared with point and sustained remission using the cross-validated area under receiver-operating curves. Results: Since 2010, 2618 RA patients started anti-TNF therapy and were followed until 2020 or until treatment discontinuation. During the first 6 months of therapy, 56% of patients had no remission (TIR = 0), and 22% of patients reached sustained remission (TIR = 1), while 22% of patients had point remissions with 0 < TIR < 1. EULAR good responders and moderate/non-responders spent 64 ± 42% and 6 ± 18% of time in remission, respectively. The mean TIR grew during the follow-up and was correlated with DAS28-CRP, SDAI, HAQ, PGA, and PhGA (P < 0.0001). TIR at 3 and 6 months predicted remission (SDAI ≤3.3) and non-disability (HAQ <0.5) at 13 and 19 months better than point or sustained remission. Conclusions: TIR is an intuitive way of estimating unobserved DA between scheduled visits; its calculation only requires two consecutive DA values (https://www.medevio.cz/tir-calculator/). TIR is a valid predictor of RA outcomes.
- 2 October 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (6) , 2295-2306
Time in remission as an alternative outcome measure for rheumatoid arthritis: a 10-year prospective study of 2618 new users of anti-TNF
Objective: Achieving targeted disease activity (DA) is the primary therapeutic strategy in RA. Point measurements of DA are done at out-patient visits, however true DA between visits remains unobserved. This study sought to describe and validate a new outcome measure, i.e. time in remission (TIR). Methods: Patients were enrolled in the Czech ATTRA-RA registry. TIR was calculated using linear interpolation of the DAS28-ESR determined at outpatient visits. Correlation coefficients were computed between TIR and DAS28-CRP, HAQ, Simple Disease Activity Index (SDAI), patient global assessment (PGA) and physician global assessment (PhGA). Using logistic regression, TIR was used as a predictor of remission (SDAI ≤3.3) and non-disability (HAQ <0.5). The predictive value of TIR was compared with point and sustained remission using the cross-validated area under receiver-operating curves. Results: Since 2010, 2618 RA patients started anti-TNF therapy and were followed until 2020 or until treatment discontinuation. During the first 6 months of therapy, 56% of patients had no remission (TIR = 0), and 22% of patients reached sustained remission (TIR = 1), while 22% of patients had point remissions with 0 < TIR < 1. EULAR good responders and moderate/non-responders spent 64 ± 42% and 6 ± 18% of time in remission, respectively. The mean TIR grew during the follow-up and was correlated with DAS28-CRP, SDAI, HAQ, PGA, and PhGA (P < 0.0001). TIR at 3 and 6 months predicted remission (SDAI ≤3.3) and non-disability (HAQ <0.5) at 13 and 19 months better than point or sustained remission. Conclusions: TIR is an intuitive way of estimating unobserved DA between scheduled visits; its calculation only requires two consecutive DA values (https://www.medevio.cz/tir-calculator/). TIR is a valid predictor of RA outcomes.
- Open Access
- 9 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3608
Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile
Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (−18%, p < 0.001), pulmonary vascular resistance (−32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.
- 9 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3608
Open AccessBalloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile
Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (−18%, p < 0.001), pulmonary vascular resistance (−32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.